Brief: Tango Therapeutics Q4 Basic EPS USD -0.35
27/02/2025 12:00
Feb 27 (Reuters) - Tango Therapeutics Q4 operating expenses USD 45.027 million. Q4 net income USD -37.67 million vs. IBES estimate USD -36.4 million Q4 operating income USD -40.91 million vs. IBES estimate USD -39.7 million
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,